OccuRx

Psyence Group Inc is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.In January 2023, Psyence Group Inc entered into a definitive business combination agreement with Psyence Biomed Corp.In april 2023, Psyence group Inc issued 9,043,038 shares at a price of CAD$0.12 per shareIn December 2022, Psyence Group Inc closed the second tranche of its previously announced private placement of CAD$3 million. The Company has issued 7,751,859 common shares at CAD$0.12 per common share for gross proceeds of CAD$930,223 in addition to the previously announced closing of the first tranche for gross proceeds of CAD$1.22 million led by Brandon Kerzner.In November 2022, the company secured subscription agreements of CAD$1.22 million in gross earnings.In January 2021, the Company issued outstanding share capital consists of 85,528,931 shares outstanding and 101,871,539 shares outstanding on a fully diluted basis

OccuRx, established in 2014, is focused on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.In May 2015, OccuRx raised AUD 6.5 million (US $5.22 million) from a funding round

Tasca Therapeuticstasca是一家私营生物技术公司，专注于发现和开发在癌症中很重要的自棕榈酰化靶蛋白的小分子抑制剂。该公司的主导项目CP-383是同类首创的候选药物，对多种癌症类型具有很好的临床前活性。